ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 362.23M | 380.48M | 375.65M | 391.00M | 261.17M |
| Total Depreciation and Amortization | 12.73M | 12.02M | 11.80M | 11.76M | 14.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -164.62M | -184.42M | -198.28M | -203.17M | -104.74M |
| Change in Net Operating Assets | -112.80M | -47.77M | -65.68M | -89.76M | 28.46M |
| Cash from Operations | 97.53M | 160.32M | 123.49M | 109.84M | 198.95M |
| Capital Expenditure | -15.55M | -14.69M | -9.90M | -4.69M | -1.14M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 146.52M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.72M | -62.78M | -102.33M | -297.87M | -269.92M |
| Cash from Investing | -84.27M | -77.47M | -112.23M | -302.56M | -124.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 49.26M | 46.81M | 52.28M | 49.88M | 29.19M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 49.26M | 46.81M | 52.28M | 49.88M | 29.19M |
| Foreign Exchange rate Adjustments | 218.00K | 59.00K | 56.00K | 26.00K | -41.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.74M | 129.72M | 63.59M | -142.82M | 103.55M |